Recombinant factor VIII concentrates.

Abstract

The development and introduction of recombinant factor VIII (rFVIII) concentrates nearly 20 years ago represented a major advance in the treatment of hemophilia A patients. Currently, first-, second- and third-generation rFVIII products are commercially available. Whereas first-generation rFVIII concentrates are stabilized with human albumin, second… (More)
DOI: 10.1055/s-0030-1255443

Topics

Cite this paper

@article{Franchini2010RecombinantFV, title={Recombinant factor VIII concentrates.}, author={Massimo Franchini and Giuseppe Lippi}, journal={Seminars in thrombosis and hemostasis}, year={2010}, volume={36 5}, pages={493-7} }